Home>Topics>Stocks>Novo Nordisk A>Novo Nordisk A/S ADR

Novo Nordisk A/S ADR NVO

  1. All
  2. Commentary
  3. Stock Reports
  4. Video Reports
  5. Fund Reports
  6. ETF Reports
  7. Headlines
    1. Sanofi: Stiff Competition Will Impact Future Performance


      Wed, 17 Sep 2014

      By Investing Tricks : Sanofi's (NYSE: SNY ) revenues are distributed through three major segments and a large chunk is attributable to the pharmaceutical segment; 85% of revenues are attributed to the pharmaceutical segment. More than half the pharmaceutical revenues are drawn from the US and ...

    2. Orexigen Therapeutics Wins Contrave Approval But Investors Should Stay Away


      Tue, 16 Sep 2014

      By Long Term Bio : Orexigen Therapeutics (NASDAQ: OREX ) received FDA approval for their obesity drug Contrave on September 10th, 2014. The FDA has finally determined that Contrave is a safe obesity drug to give to patients to help reduce their weight. Orexigen Therapeutics has been struggling to

    3. New Diabetes Drugs Gain Approval - Florins Versus Oral Insulin


      Sun, 14 Sep 2014

      By Sharon di Stefano : Pharmaceutical companies are adept at rolling out new classes of drugs, despite potential harmful side effects, and Eli Lilly and Co. (NYSE: LLY ) is no exception. Just recently, Lilly began selling Jardiance, a once-daily tablet for Type 2 diabetics, a 'flozin', with an ...

    4. Novo Gets Positive Vote From FDA For Anti-Obesity Treatment - Still A Long Road Ahead


      Fri, 12 Sep 2014

      By Spencer Osborne : Novo Nordisk (NYSE: NVO ) received good news earlier this week in its quest to get an obesity indication for its drug Saxenda. The drug is a different

    5. Ad Comm gives thumbs up to Novo's obesity drug candidate


      Thu, 11 Sep 2014

      The FDA's Endocrinologic and Metabolic Drugs Advisory Committee concludes that Novo Nordisk's ( NVO +1.8% ) obesity drug Saxenda (liraglutide) is safe and effective enough to warrant approval . Post your comment!

    6. Arena Pharmaceuticals - A Biotech Value Investment


      Wed, 10 Sep 2014

      By KLLJ Investments : It has been some time since I have written an article covering Arena Pharmaceuticals (NASDAQ: ARNA ), and I have recently received inquiries asking if I still believe in the company and the prospects for its lead drug, Belviq. Given the stock is hitting 52-week lows, despite

    7. Ad Comm meeting approaches for Novo's obesity treatment candidate


      Tue, 9 Sep 2014

      The FDA's Endocrinologic and Metabolic Drugs Advisory Committee meets this Thursday to discuss Novo Nordisk's ( NVO +2.3% ) NDA for Saxenda ( liraglutide ) as an adjunct to a reduced-calorie diet and increased physical activity for chronic

    8. Novo stops development activities in inflammatory disorders


      Tue, 2 Sep 2014

      inflammatory diseases space after discontinuing anti-IL-20 for the treatment of rheumatoid arthritis, Novo Nordisk (NYSE: NVO ) decides to discontinue its R&D efforts in the area. EVP and CSO Mads Krogsgaard Thomsen says, "The discontinuation of

    9. Novo Nordisk: The Case For Predictability In Earnings


      Tue, 26 Aug 2014

      they're even busier handing out insulin with the other. Not-so-famously, Denmark is also home to Novo Nordisk (NYSE: NVO ), the world's largest player in the diabetes care market. With the share price up more than 20% year-to-date, Novo

    10. Update: China Biologic Acquires Additional Interest In Guizhou Facility - Shares Rise


      Tue, 26 Aug 2014

      risks to an investment in China Biologic, given that the plasma space is home to Baxter (NYSE: BAX ) and Novo Nordisk (NYSE: NVO ), which market internationally ADVATE and NovoSeven, NovoEight and NovoThirteen, respectively. Nevertheless, the latest

    « Prev12345Next »
    Content Partners